Inhibiting Arginine Methylation as a Tool to Investigate Cross-Talk with Methylation and Acetylation Post-Translational Modifications in a Glioblastoma Cell Line

Glioblastomas (GBM) are the most common grade 4 brain tumours; patients have very poor prognosis with an average survival of 15 months after diagnosis. Novel research lines have begun to explore aberrant protein arginine methylation (ArgMe) as a possible therapeutic target in GBM and ArgMe inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Samuel, Sabrina Francesca, Marsden, Alistair James, Deepak, Srihari, Rivero, Francisco, Greenman, John, Beltran-Alvarez, Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313862/
https://www.ncbi.nlm.nih.gov/pubmed/30347783
http://dx.doi.org/10.3390/proteomes6040044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313862/
https://www.ncbi.nlm.nih.gov/pubmed/30347783
http://dx.doi.org/10.3390/proteomes6040044

Ejemplares similares